ArticleAmerican journal of translational research2022

Effect of bevacizumab plus paclitaxel and carboplatin regimen on prognostic survival of ovarian cancer patients.

Qingling Jiang et al.PubMed ↗Full text ↗

No numbers read from the abstract.